RKDA · Arcadia Biosciences, Inc.

Revenue of $1.1 million in Q1 2026 declined 8.3% from $1.2 million in the prior-year quarter. This reflects the company's business model where revenues fluctuate based on the timing of product shipments to customers and are reported net of estimated chargebacks, returns, and losses. Sales volumes are generally highest in the second and third fiscal quarters due to warmer weather patterns, positioning Q1 as a seasonally softer period.

Operating income swung to a loss of $779 thousand from a $530 thousand profit, a 247.0% deterioration that produced an operating margin of -70.8%. This shift underscores the impact of non-recurring prior-year items no longer present, amplifying expense pressures relative to the modestly lower revenue base.

The net loss widened sharply to $4.4 million from a $2.6 million profit, with diluted EPS at -$2.11 versus $1.90—a 211.1% decline. This reflects volatility from one-time financing-related losses and other non-operating items, distorting the underlying operational performance seen in the revenue and gross profit trends.

Cash flow from operations used $1.1 million, an improvement from $1.6 million in the prior year, indicating better working capital management. The company continues to fund operations primarily through net proceeds from private and public equity offerings, alongside product sales and license agreement payments. This reliance on external financing highlights persistent liquidity pressures in a period of profitability challenges and segment-specific cost dynamics centered on Zola.

Overall, these results emphasize the need for sustained Zola volume growth into peak seasons while navigating cost discipline and capital needs, as the business model ties performance closely to shipment timing and external funding sources.